Comparative Efficacy and Safety of Moxifloxacin and Levofloxacin in a Short Standardised Rifampicin Resistant TB Regimen: A STREAM 2 Secondary Analysis

(1) Background: The World Health Organisation (WHO) categorises moxifloxacin and levofloxacin as Group A drugs, which should be prioritised in the treatment of rifampicin-resistant tuberculosis. We compare their relative efficacy and safety using data from the STREAM trial; (2) Methods: Marginal str...

Full description

Bibliographic Details

Published in:	Tropical Medicine and Infectious Disease
Main Authors:	Stella M. Fabiane, Chen-Yuan Chiang, Sarah K. Meredith, Meera Gurumurthy, Adamu Bayissa, Andrew J. Nunn, Ruth L. Goodall
Format:	Article
Language:	English
Published:	MDPI AG 2024-09-01
Subjects:	moxifloxacin levofloxacin efficacy treatment outcomes safety treatment outcomes
Online Access:	https://www.mdpi.com/2414-6366/9/9/211